Meet our CEO at Nordic Life Science Days on 20-23 April

Read More

Cyxone CEO Tara Heitner will update our progress at the Redeye Investor Forum Online on April 29th at 13.20 CET

Read More

Enjoy Tara’s company presentation at BioStock Live on March 9

Read More

Cyxone – an innovative clinical-stage biotech company

Cyxone develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. With three unique programs, Cyxone is well positioned to deliver substantial benefits for patients, the health care system as well as for its shareholders.

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More

CEO Tara Heitner comments

In a future where the Covid-19 pandemic hopefully lies behind us, there will still be a need for efficient drugs in patients suffering from acute respiratory distress as a result from other infections, such as a seasonal influenza.

Read More